Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041795 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yajing Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Receptor, Metabotropic Glutamate 5, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Chief Scientist Research Project of Hubei Shizhen Laboratory, the Key Scientific and Technological Project of Hubei Shizhen Laboratory, the Scientific Research Start-up Fund for Talents of Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
The incidence and mortality rates of lung adenocarcinoma (LUAD) continue to rise, highlighting an urgent need for novel therapeutic targets. In this study, bioinformatics analysis revealed that members of the metabotropic glutamate receptor (mGluR) family are significantly correlated with the expression profile, prognosis, genetic mutations, and tumor immune microenvironment of LUAD, with GRM5 being the most significantly associated member. Overexpression of GRM5 has been shown to inhibit LUAD proliferation and induce apoptosis, while cinchonine (CN) treatment further enhances these effects, suggesting that CN may act as a GRM5 agonist to synergistically exert antitumor activity. Transcriptome sequencing further identified four key downstream targets and their associated signaling pathways. In summary, this study confirms that GRM5 can serve as a potential prognostic biomarker and therapeutic target for LUAD, while the small-molecule compound CN shows promise as an antitumor candidate drug targeting GRM5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Hubei Shizhen Laboratory, Wuhan 430061, China.
ORCID-Profile: Chi Song
Förderung
- the Chief Scientist Research Project of Hubei Shizhen Laboratory
- the Key Scientific and Technological Project of Hubei Shizhen Laboratory
- the Scientific Research Start-up Fund for Talents of Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Xue, Y., Liu, W., Wang, Y., Tao, P., Yuan, Y., Liu, C., Chen, S., & Song, C. (2026). Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041795
Vancouver
Xue Y, Liu W, Wang Y, Tao P, Yuan Y, Liu C, et al. Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041795
BibTeX
@article{Xue2026,
author = {Xue, Yajing and Liu, Wei and Wang, Yongfu and Tao, Pengzhuo and Yuan, Yizhen and Liu, Changmin and Chen, Shilin and Song, Chi},
title = {Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041795}
}
EUVIMED